Non-Hodgkin Lymphoma — An Interview with Dr John P Leonard on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting (Companion Faculty Lecture)

Featuring a slide presentation and related discussion from Dr John P Leonard, including the following topics:

• Five-year analysis of the POLARIX trial of polatuzumab vedotin with R-CHP for previously untreated diffuse large B-cell lymphoma (0:00)
• Epcoritamab, glofitamab and other bispecific antibodies for large B-cell lymphoma (5:33)
• Circulating tumor DNA as an early outcome predictor in patients with large B-cell lymphoma receiving second-line lisocabtagene maraleucel in the TRANSFORM study (16:44)
• The bispecific antibodies mosunetuzumab and odronextamab as initial therapy for follicular lymphoma (FL) (19:27)
• The Phase III inMIND trial of tafasitamab in combination with lenalidomide/rituximab for recurrent FL (22:58)
• Updated results from studies of bispecific antibodies and chimeric antigen receptor T-cell therapy for relapsed/refractory FL (24:58)
• Updates from the Phase III TRIANGLE and ECOG-ACRIN EA4151 trials on the role of autologous stem cell transplant in the treatment of previously untreated mantle cell lymphoma (MCL) (27:48)
• Novel treatment approaches with Bruton tyrosine kinase inhibitors for patients with newly diagnosed MCL (30:53)

CME information and select publications